BACKGROUND: Forkhead box (FOXP3) is considered to be a specific marker for regulatory T cells. The aim of this study was to correlate intragraft FOXP3 at mRNA and cellular levels during renal allograft rejection to response to therapy and late clinical outcome. METHODS: Immunostainings and quantitative reverse-transcriptase polymerase chain reaction for FOXP3, CD3, and transforming growth factor (TGF)-beta were performed and results were related to histopathologic and clinical outcome. RESULTS: A good correlation between immunohistochemical analysis and mRNA levels for both CD3 and FOXP3 was observed. Intragraft FOXP3 was significantly related to tubulitis and interstitial fibrosis. A strong correlation was found between FOXP3 and CD3 mRNA and between FOXP3 and TGF-beta mRNA. No correlation was found between FOXP3 and response to therapy. DISCUSSION: In conclusion, intragraft FOXP3 at both cellular and molecular levels parallels T-cell infiltration during acute rejection. FOXP3 does not predict response to antirejection therapy. FOXP3 correlates with renal fibrosis, TGF-beta, and poor late renal outcome.
BACKGROUND: Forkhead box (FOXP3) is considered to be a specific marker for regulatory T cells. The aim of this study was to correlate intragraft FOXP3 at mRNA and cellular levels during renal allograft rejection to response to therapy and late clinical outcome. METHODS: Immunostainings and quantitative reverse-transcriptase polymerase chain reaction for FOXP3, CD3, and transforming growth factor (TGF)-beta were performed and results were related to histopathologic and clinical outcome. RESULTS: A good correlation between immunohistochemical analysis and mRNA levels for both CD3 and FOXP3 was observed. Intragraft FOXP3 was significantly related to tubulitis and interstitial fibrosis. A strong correlation was found between FOXP3 and CD3 mRNA and between FOXP3 and TGF-beta mRNA. No correlation was found between FOXP3 and response to therapy. DISCUSSION: In conclusion, intragraft FOXP3 at both cellular and molecular levels parallels T-cell infiltration during acute rejection. FOXP3 does not predict response to antirejection therapy. FOXP3 correlates with renal fibrosis, TGF-beta, and poor late renal outcome.
Authors: M Chen; M Mohtize; M-F Matteï; J-P Villemot; C Kohler; G C Faure; M C Béné; M de Carvalho Bittencourt Journal: Clin Exp Immunol Date: 2010-10-29 Impact factor: 4.330
Authors: Pablo J E J van de Berg; Eveline C Hoevenaars; Si-La Yong; Karlijn A M I van Donselaar-van der Pant; Anne van Tellingen; Sandrine Florquin; René A W van Lier; Fréderike J Bemelman; Ineke J M ten Berge Journal: Immunology Date: 2012-06 Impact factor: 7.397
Authors: Onno J de Boer; Peter Teeling; Marcel Jansen; Hanneke Ploegmakers; Chris M van der Loos; J Alain Kummer; Sandrine Florquin; Allard C van der Wal Journal: PLoS One Date: 2011-04-06 Impact factor: 3.240
Authors: Henry J McSorley; Soraya Gaze; James Daveson; Dianne Jones; Robert P Anderson; Andrew Clouston; Nathalie E Ruyssers; Richard Speare; James S McCarthy; Christian R Engwerda; John Croese; Alex Loukas Journal: PLoS One Date: 2011-09-16 Impact factor: 3.240
Authors: Danny Luan; Darshana M Dadhania; Ruchuang Ding; Thangamani Muthukumar; Michelle Lubetzky; John R Lee; Vijay K Sharma; Phyllis August; Franco B Mueller; Joseph E Schwartz; Manikkam Suthanthiran Journal: Transplantation Date: 2021-08-01 Impact factor: 5.385
Authors: Devon M Headen; Kyle B Woodward; María M Coronel; Pradeep Shrestha; Jessica D Weaver; Hong Zhao; Min Tan; Michael D Hunckler; William S Bowen; Christopher T Johnson; Lonnie Shea; Esma S Yolcu; Andrés J García; Haval Shirwan Journal: Nat Mater Date: 2018-06-04 Impact factor: 43.841